Lannett Entered into a Patent License Agreement with Ypsomed and HEC for Pen Injector Device in Use of Biosimilar Insulin Glargine and Insulin Aspart
Shots:
- Lannett entered into a patent license agreement with Ypsomed and its strategic partner within HEC for a pen injector delivery device to be used for its insulin glargine and insulin aspart development program
- In return for its financial contribution, Lannett and HEC will receive a sub-license under the arrangement b/w Ypsomed and Sanofi-Aventis Deutschland GmbH which was the owner of several patents relating to the pen injector device
- The company is expected the results at the end of 2022 with an expected filing of the BLA for a biosimilar and interchangeable insulin glargine to Sanofi's Lantus in 2023 and the product is expected to be launched in H1’24
Ref: PR Newswire | Image: Lannett
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
